Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4179062 | 0.88 | KDM4E (0.43) | KDM4EGBA1ROCK2MAPTMEN1 | |
| SCHEMBL1630883 | 0.88 | ROCK2 (0.35) | GBA1ROCK2MAPTCSNK2A2CSNK2A1 | |
| SCHEMBL1630619 | 0.88 | GBA1 (0.42) | GBA1ROCK2CSNK2A2CSNK2A1ROCK1 | |
| SCHEMBL1630053 | 0.83 | ROCK2 (0.37) | GBA1ROCK2CSNK2A2CSNK2A1ROCK1 | |
| SCHEMBL1631686 | 0.80 | GBA1 (0.43) | GBA1ROCK2CSNK2A2CSNK2A1ROCK1 | |
| SCHEMBL1887474 | 0.80 | KDM4E (0.48) | KDM4EGBA1MAPTMEN1KMT2A | |
| SCHEMBL12724718 | 0.79 | KDM4E (0.46) | KDM4EROCK2MAPTMEN1KMT2A | |
| SCHEMBL1888574 | 0.79 | KDM4E (0.53) | KDM4EGBA1MAPTMEN1KMT2A | |
| SCHEMBL1887405 | 0.77 | KDM4E (0.51) | KDM4EGBA1MAPTMEN1KMT2A | |
| SCHEMBL4185997 | 0.77 | GBA1 (0.46) | KDM4EGBA1ROCK2L3MBTL1CSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932270-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2011-04-26 | — | — | US | claimed |
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-01-08 | — | — | US | claimed |
| US-7932270-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | KDM4E 3309/4885GBA1 4031/4885ROCK2 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.